Sudeep Pharma Ltd

Sudeep Pharma Other Announcement

Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.

Sudeep Pharma Investor Presentation: Key Takeaways

Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).

Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY

Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.

Key figure

Net profit ₹40.6 Cr · +29.7% YoY

Sudeep Pharma Earnings Call Transcript: Key Takeaways

Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.

Sudeep Pharma Earnings Call: Key Takeaways

Sudeep Pharma reported 27.9% YoY revenue growth in FY26 to ₹642.3cr, driven by specialty ingredients and international expansion. Management is pivoting towards high-value mineral molecules and a major entry into battery materials.

Sudeep Pharma Earnings Call: Key Takeaways

Sudeep Pharma reported record FY26 revenue of ₹642.3cr, driven by the listing, the NSS acquisition, and expansion into battery materials.

Sudeep Pharma Q4 FY26 Results: Net Profit ₹48.5 Cr, Up 9.7% YoY

Sudeep Pharma Ltd reported revenue from operations of ₹182.3 Cr (+15.7% YoY) and net profit of ₹48.5 Cr (+9.7% YoY) for Q4 FY26.

Key figure

Net profit ₹48.5 Cr · +9.7% YoY

Sudeep Pharma Earnings Call: Key Takeaways

Sudeep Pharma debuted with solid Q2 performance but faced temporary US tariff headwinds. Management is pivoting from pure excipients to high-value specialty ingredients and battery materials via a new Dahej facility.